Cost Effectiveness of Ceftolozane/Tazobactam Compared With Meropenem for the Treatment of Patients With Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

<div><b>Article full text</b></div><div><br></div><div>The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). </div><div>© The authors, CC-BY-NC 2021. </div>